ArticleTaiwan journal of ophthalmology
Remission of myasthenia gravis following infection with SARS-CoV-2: A case report.
Article in Taiwan journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report describes an unprecedented remission of ocular Myasthenia Gravis (MG) in a 3-year-old girl following a SARS-CoV-2 infection. Both MG and SARS-CoV-2 influence the cholinergic system, and this case underscores the importance of considering multiple factors in autoimmune disorders and the potential impact of viral infections on their course. The patient initially presented with ptosis and limited eye movement. Her diagnosis of seronegative MG was confirmed with abnormal visual evoked potentials and positive response to pyridostigmine. Her ptosis and limited extraocular muscle movement were intermittent until 2 years later when she tested positive for SARS-CoV-2 for which no antiviral medication was taken. Unexpectedly, her MG symptoms rapidly improved postinfection, leading to the cessation of pyridostigmine. This case highlights the complex interplay between MG, viral infections, and the influence of anti-acetylcholine receptor antibodies, second-hand smoke, and natural nicotinic agonists from the use of pyridostigmine on the cholinergic system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.